ANCOR Platinum Partner Jazz Pharmaceuticals has developed EPIDIOLEX, the first and only FDA approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).
During this webinar you’ll hear from Jazz Pharmaceuticals and Nanette Wrobel, registered pharmacist for Tarrytown Expocare Pharmacy. They will discuss the latest updates regarding EPIDIOLEX, cannabinoid science, results from randomized clinical trials, plus labeling information.
Register to join this webinar, Thursday, May 26 at 1 pm EDT!
Stay Informed on the Latest Research & Analysis from ANCOR
ANCOR Platinum Partner Jazz Pharmaceuticals has developed EPIDIOLEX, the first and only FDA approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).
